InnovAge Holding (INNV) has drawn fresh attention after reporting third quarter results and lifting its fiscal 2026 revenue outlook to US$950 million to US$975 million, while quarterly net loss widened due to higher legal and litigation expenses.

The stock has cooled slightly after the earnings and guidance update, with a 1-day share price return of 0.49% decline and a 7-day share price return of 0.86% decline. However, the year-to-date share price return of 55.68% and 1-year total shareholder return of 126.33% indicate momentum that has built over a longer period despite recent volatility.

If this mix of strong recent total shareholder returns and litigation-related risks has your attention, it may be worth broadening your search with the 35 healthcare AI stocks

So with revenue guidance raised, profitability pressured by legal costs, and the stock trading below analyst targets but above some intrinsic estimates, should you see InnovAge as undervalued or has the market already priced in future growth?

Most Popular Narrative: 15.4% Overvalued

Analysts see fair value for InnovAge at $7.00, which sits below the last close of $8.08, setting up a clear valuation gap to unpack.

Geographic expansion into new markets and underpenetrated states, coupled with improved enrollment efficiency, is enabling InnovAge to leverage its existing infrastructure for scalable growth, setting the stage for higher long-term revenue and operating leverage.

Curious what kind of revenue path and margin lift analysts are baking in to reach that fair value, and how the future earnings multiple fits into the story.

Result: Fair Value of $7.00 (OVERVALUED)

However, there are still clear tension points, including higher legal and compliance costs and losses from new center openings, which could challenge the current overvaluation story.

Another Take: Multiples Point to a Very Different Story

While the analyst narrative pegs InnovAge as 15.4% overvalued at $7.00, the P/S ratio tells a different story. The stock trades on 1.2x sales, above the peer average of 1.1x, yet below a fair ratio of 2.4x. This hints at both valuation risk and potential upside if sentiment shifts.

For a closer look at how this pricing compares and where the market could move, see the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly split between valuation risk and potential reward, it makes sense to check the numbers yourself and decide quickly where you stand. You can start with the 2 key rewards.

Looking for more investment ideas?

Do not stop your research with a single stock. Broaden your watchlist with fresh ideas that fit different goals and risk levels.

• Target potential mispricings by checking out the 51 high quality undervalued stocks that combine quality fundamentals with attractive valuations.
• Prioritise resilience and capital protection by reviewing the 71 resilient stocks with low risk scores designed to highlight companies with lower risk scores.
• Pursue growth away from the usual crowd by scanning the screener containing 23 high quality undiscovered gems before other investors start paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.